Taysha Gene Therapies, Inc.

    Jurisdiction
    United States
    ISIN
    US8776191061 (TSHA)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €6.91M
    Gross margin
    96.6%
    EBIT
    -€80.18M
    EBIT margin
    -1,160.8%
    Net income
    -€79.09M
    Net margin
    -1,145.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €4.14M -40.1% -€110.87M +40.2%
    €62.45M +1,409.7% -€76.13M -31.3%
    €105.19M +68.4% -€70.79M -7.0%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Alam Kamran CHIEF FINANCIAL OFFICER -54K $2.85 -$155.30K
    Nagendran Sukumar President and Head of R&D -57K $2.85 -$162.60K

    Earnings Calls

    Latest earnings call: May 14, 2024

    Add to watchlist

    Notifications